Orexigen Therapeutics, which is developing two drugs for the treatment of obesity, priced its IPO at $12.00 per share, the midpoint of the proposed $11.00 to $13.00 range, Wednesday evening. The company sold 7 million shares, 17% more than the 6 million originally planned. Merrill Lynch was the lead manager on the deal. The stock is expected to begin trading on the NASDAQ under the ticker "OREX" on Thursday.
